HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva access trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

OSI/Genentech's new Phase IIIb Tarceva trial, announced Sept. 10, is intended to provide access to the non-small cell lung cancer therapy before approval, Genentech says. Patients will be enrolled in the open-label Access to Care, Tarceva (ACT) study up until FDA's decision, which is expected in early 2005, and may remain in the study until nine months post-approval. Survival and response rates are co-primary endpoints. Although Tarceva (erlotinib) showed a two month survival benefit in its pivotal study, the design of the trial would make it easier to collect additional survival data after commercial approval. An earlier Phase III combination study did not show a survival benefit (1Pharmaceutical Approvals Monthly Feb. 1, 2004, In Brief). Genentech plans to submit the data at the end of the study...
Advertisement

Related Content

Tarceva NDA gets rolling

Topics

Advertisement
UsernamePublicRestriction

Register

PS002656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel